Real-Time Monitoring of Antibiotics in the Critically Ill Using Biosensors

By ensuring optimal dosing, therapeutic drug monitoring (TDM) improves outcomes in critically ill patients by maximizing effectiveness while minimizing toxicity. Current methods for measuring plasma drug concentrations, however, can be challenging, time-consuming, and slow to return an answer, limit...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruvimbo Dephine Mishi (Author), Michael Andrew Stokes (Author), Craig Anthony Campbell (Author), Kevin William Plaxco (Author), Sophie Lena Stocker (Author)
Format: Book
Published: MDPI AG, 2023-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8bdd63dd3f054fd7adfb2dbd0ed85f74
042 |a dc 
100 1 0 |a Ruvimbo Dephine Mishi  |e author 
700 1 0 |a Michael Andrew Stokes  |e author 
700 1 0 |a Craig Anthony Campbell  |e author 
700 1 0 |a Kevin William Plaxco  |e author 
700 1 0 |a Sophie Lena Stocker  |e author 
245 0 0 |a Real-Time Monitoring of Antibiotics in the Critically Ill Using Biosensors 
260 |b MDPI AG,   |c 2023-09-01T00:00:00Z. 
500 |a 10.3390/antibiotics12101478 
500 |a 2079-6382 
520 |a By ensuring optimal dosing, therapeutic drug monitoring (TDM) improves outcomes in critically ill patients by maximizing effectiveness while minimizing toxicity. Current methods for measuring plasma drug concentrations, however, can be challenging, time-consuming, and slow to return an answer, limiting the extent to which TDM is used to optimize drug exposure. A potentially promising solution to this dilemma is provided by biosensors, molecular sensing devices that employ biorecognition elements to recognize and quantify their target molecules rapidly and in a single step. This paper reviews the current state of the art for biosensors regarding their application to TDM of antibiotics in the critically ill, both as ex vivo point-of-care devices supporting single timepoint measurements and in vivo devices supporting continuous real-time monitoring in situ in the body. This paper also discusses the clinical development of biosensors for TDM, including regulatory challenges and the need for standardized performance evaluation. We conclude by arguing that, through precise and real-time monitoring of antibiotics, the application of biosensors in TDM holds great promise for enhancing the optimization of drug exposure in critically ill patients, offering the potential for improved outcomes. 
546 |a EN 
690 |a biosensor 
690 |a therapeutic drug monitoring 
690 |a antibiotic 
690 |a intensive care unit 
690 |a critically ill 
690 |a aptamers 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antibiotics, Vol 12, Iss 10, p 1478 (2023) 
787 0 |n https://www.mdpi.com/2079-6382/12/10/1478 
787 0 |n https://doaj.org/toc/2079-6382 
856 4 1 |u https://doaj.org/article/8bdd63dd3f054fd7adfb2dbd0ed85f74  |z Connect to this object online.